1-4 of 4
Siu-Long Yao
Close
Sort by
Journal Articles

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Jorge E. Cortes, Tapan Saikia, Dong-Wook Kim, Yesid Alvarado, Franck E. Nicolini, Krishnakumar Rathnam, Navin Khattry, Sachin Punatar, Jane F. Apperley, Aude Charbonnier, Michael Deininger, Hugues de Lavallade, Nikki Granacher, Carlo Gambacorti-Passerini, Alessandro Lucchesi, Michael Mauro, Peter Vandenberghe, Gregor Verhoef, Andrew R. Whiteley, Arijit Nag, Shashikant Apte, Siu-Long Yao, Sandeep Inamdar, Ruchika Irene Dillu, Jayasree Sreenivasan, Geetanjali Chimote
Journal: Blood
Blood (2022) 140 (Supplement 1): 205–207.
https://doi.org/10.1182/blood-2022-166452
Published: 2022
Journal Articles

An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies

Jorge E. Cortes, Tapan Saikia, Dong-Wook Kim, Yesid Alvarado, Franck E. Nicolini, Krishnakumar Rathnam, Navin Khattry, Jane F Apperley, Michael W. Deininger, Hugues de Lavallade, Aude Charbonnier, Nikki Granacher, Carlo Gambacorti-Passerini, Alessandro Lucchesi, Michael J. Mauro, Peter Vandenberghe, Gregor Verhoef, Andrew R. Whiteley, Arijit Nag, Vivek S Radhakrishnan, Shashikant Apte, Siu-Long Yao, Sandeep Inamdar, Jayasree Sreenivasan, Ruchika Irene Dillu, Geetanjali Chimote
Journal: Blood
Blood (2021) 138 (Supplement 1): 309.
https://doi.org/10.1182/blood-2021-152548
Published: 2021
Journal Articles

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Jorge E. Cortes, MD, Tapan Saikia, MD, Dong-Wook Kim, MD, Yesid Alvarado, MD, Franck E Nicolini, MDPhD, Navin Khattry, MD DM, Krishnakumar Rathnam, MD DM, Jane Apperley, FRCP, FRCPath, MB, Michael W. Deininger, MD PhD, Hugues de Lavallade, MD PhD, Aude Charbonnier, MD PhD, Nikki Granacher, MD, Carlo Gambacorti-Passerini, MD, Alessandro Lucchesi, MD, Michael J. Mauro, MD, Gregor Verhoef, MD PhD, Peter Vandenberghe, MD, Andrew R. Whiteley, MD, Shashikant Apte, MD FRCPA, Siu-Long Yao, MD, Mudgal Kothekar, MD, Jayasree Sreenivasan, MSc, Bimba HV, MD, Geetanjali Chimote, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 51–52.
https://doi.org/10.1182/blood-2020-139847
Published: 2020
Journal Articles

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Jorge E. Cortes, MD, Dong-Wook Kim, Franck E Nicolini, MD PhD, Tapan Saikia, MD, Aude Charbonnier, Jane F. Apperley, MD FRCP, FRCPath, MB, Krishna Rathnam, Michael W. Deininger, Hugues De Lavallade, Navin Khattry, MD DM MDcal Oncology, Andrew Whiteley, MD, Michael J. Mauro, MD, Gregor Verhoef, MD PhD, Carlo Gambacorti-Passerini, MD, Alessandro Lucchesi, MD, Shashikant Apte, MD FRCPA, Granacher Nikki, Siu-Long Yao, MD, Mudgal Kothekar, MD, Jayasree Sreenivasan, Msc, Bimba HV, MD, Geetanjali Chimote, MBBS, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4158.
https://doi.org/10.1182/blood-2019-129751
Published: 2019